abrdn plc Increases Stock Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

abrdn plc grew its position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 9.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 600,700 shares of the company’s stock after purchasing an additional 50,000 shares during the period. abrdn plc’s holdings in Tenaya Therapeutics were worth $859,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in TNYA. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock worth $651,000 after purchasing an additional 226,466 shares during the period. Wellington Management Group LLP lifted its position in Tenaya Therapeutics by 35.6% in the third quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock worth $568,000 after buying an additional 77,235 shares during the last quarter. Walleye Capital LLC purchased a new position in Tenaya Therapeutics during the third quarter worth $134,000. Geode Capital Management LLC boosted its stake in Tenaya Therapeutics by 5.4% during the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock worth $2,502,000 after buying an additional 66,968 shares during the period. Finally, Spire Wealth Management bought a new position in Tenaya Therapeutics during the fourth quarter valued at $53,000. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Stock Performance

NASDAQ TNYA opened at $0.90 on Tuesday. Tenaya Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $7.01. The firm has a market capitalization of $71.07 million, a P/E ratio of -0.62 and a beta of 2.84. The stock has a 50-day simple moving average of $1.73 and a two-hundred day simple moving average of $2.16.

Wall Street Analysts Forecast Growth

TNYA has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday, February 3rd. Chardan Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Tenaya Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.